<DOC>
	<DOC>NCT00664573</DOC>
	<brief_summary>To observe the long-term treatment with BG9924 when administered to participants with RA who previously participated in a Biogen Idec Study.</brief_summary>
	<brief_title>104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Must be a participant from Study 104RA202 (NCT 00664716) Stable dose of Methotrexate for the duration of the study Participants with a significant change in their medical history from their previous BG9924 study Any clinically significant infectious illness or serious local infection NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Safety</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Baminercept alfa</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>BG9924</keyword>
	<keyword>Efficacy</keyword>
</DOC>